scholarly journals Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Bhavin R. Shastri ◽  
Subhashini Yaturu
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Androgen Deprivation ◽  
Metabolic Changes ◽  
Therapeutic Modality ◽  
Cardiovascular Risks ◽  
Metabolic Complications ◽  
Treat Prostate Cancer

Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen dependence of prostate cancer in 1941. That led to the utilization of androgen deprivation therapy as an important therapeutic modality to treat prostate cancer. Androgen deprivation therapy has additional systemic effects that include sexual dysfunction, psychological changes and more important are the metabolic changes. Metabolic changes in particular include insulin resistance, increase fat mass and low-density lipoprotein cholesterol, and induce type 2 diabetes. In this review we will focus on the cardiovascular risk associated with androgen deprivation therapy that includes the mechanisms involved.

scholarly journals Fasting Blood Glucose and Lipid Profile Alterations following Twelve-Month Androgen Deprivation Therapy in Men with Prostate Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Hasan S. Sağlam ◽  
Osman Köse ◽  
Şükrü Kumsar ◽  
Salih Budak ◽  
Öztuğ Adsan
Keyword(s):  
Prostate Cancer ◽  
Blood Glucose ◽  
Androgen Deprivation Therapy ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Androgen Deprivation ◽  
Blood Cholesterol

Purpose.In this retrospective study, we aimed to investigate the effects of androgen deprivation therapy (ADT) on blood glucose and blood cholesterol levels over a 12-month period.Materials and Methods.Between January 2010 and June 2012, the data of 44 patients with prostate cancer who were receiving ADT were collected from a hospital database. Patients with additional malignancy or diabetes and those who had been prescribed and were currently taking cholesterol-lowering medication were excluded from the study. Data (including fasting blood glucose levels and a cholesterol profile) were collected and analysed statistically. A value <0.05 was considered statistically significant.Results.Twelve months after the initiation of ADT, fasting blood glucose (FBG), total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) levels changed. FBG, TC, LDL cholesterol, and TG increased significantly (, 0.000, 0.000, and 0.000, resp.), while HDL cholesterol decreased ().Conclusion.ADT may increase FBG, TC, LDL cholesterol, and TG but decrease HDL cholesterol by the end of a year of treatment. Therefore, close followup may be needed as a consequence of one-year ADT regarding metabolic alterations.

scholarly journals A qualitative study exploring men’s experience of sexual dysfunction as a result of radiotherapy and androgen deprivation therapy to treat prostate cancer

2020 ◽  
pp. 1-4
Author(s):  
W. Kinnaird ◽  
A. Stewart-Lord
Keyword(s):  
Prostate Cancer ◽  
Sexual Dysfunction ◽  
Qualitative Study ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Post Treatment ◽  
Self Perception ◽  
Treat Prostate Cancer ◽  
Treatment Changes ◽  
A Priority

Abstract Aim: Sexual dysfunction is a common side effect of external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) to treat prostate cancer. Men are likely to experience erectile dysfunction, low libido, ejaculatory problems and penile shortening. This qualitative study explored men’s perceptions of sexual dysfunction, including factors such as self-perception, relationships and information and support needs. Methods: Semi-structured interviews were carried out with n = 8 men living 18–30 months after EBRT ± ADT. The interviews were transcribed and thematic analysis was carried out. Results: All men experienced sexual dysfunction following treatment. The main themes arising were: (i) priorities—sexual issues were not a priority when making treatment decisions, (ii) information and support—men described a lack of information and support about sexual dysfunction and (iii) impact—sexual dysfunction impacted on their self-perception and relationships. Findings: Men undergoing EBRT/ADT for prostate cancer may be affected by post-treatment changes in sexual function in a range of ways. This study suggests that they would benefit from early and wide-ranging information and support on sexual dysfunction, even if they do not consider it as a priority. Candid discussions about self-perception and relationships, as well as physical changes, may equip them to cope with post-treatment changes.

scholarly journals Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

2016 ◽  
Vol 10 (9-10) ◽  
pp. 300 ◽  
Author(s):  
Mohammadali Mohammadzadeh Rezaei ◽  
Mohammadhadi Mohammadzadeh Rezaei ◽  
Alireza Ghoreifi ◽  
Behzad Feyzzadeh Kerigh
Keyword(s):  
Prostate Cancer ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Safe Alternative ◽  
Metabolic Complications ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Blood Pressures

<p><strong>Introduction:</strong> The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.</p><p><strong>Methods:</strong> In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.</p><p><strong>Results:</strong> Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six- and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.</p><p><strong>Conclusions:</strong> Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.</p>

scholarly journals Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients

2020 ◽  
Vol 1874 (1) ◽  
pp. 188383
Author(s):  
Sakthivel Muniyan ◽  
Lei Xi ◽  
Kaustubh Datta ◽  
Anindita Das ◽  
Benjamin A. Teply ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Cardiovascular Risks

scholarly journals Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis

2008 ◽  
Vol 93 (6) ◽  
pp. 2042-2049 ◽  
Author(s):  
Sadeka Shahani ◽  
Milena Braga-Basaria ◽  
Shehzad Basaria
Keyword(s):  
Prostate Cancer ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Cardiovascular Mortality ◽  
Prospective Studies ◽  
Androgen Deprivation ◽  
Negative Consequences ◽  
Metabolic Complications

Abstract Context: Prostate cancer (PCa) is the most common cancer in men. Androgen-deprivation therapy (ADT) is generally employed in the treatment of locally advanced and metastatic PCa. Although its use as an adjuvant therapy has resulted in improved survival in some patients, ADT has negative consequences. Complications like osteoporosis, sexual dysfunction, gynecomastia, and adverse body composition are well known. Recently, metabolic complications like insulin resistance, diabetes, dyslipidemia, and metabolic syndrome have emerged, which may be responsible for the increased cardiovascular mortality in this population. Evidence Acquisition: A MEDLINE search was conducted for articles published over the last 20 yr based on the key words androgen deprivation therapy AND insulin resistance, hyperglycemia, diabetes, dyslipidemia, metabolic syndrome, and cardiovascular disease. Relevant studies in non-PCa populations evaluating the association between testosterone and metabolism were also reviewed and briefly mentioned where relevant. Evidence Synthesis: Prospective studies evaluating early (3–6 months) metabolic changes of ADT show development of hyperinsulinemia; however, glucose levels remain normal. Cross-sectional studies of men undergoing long-term (≥12 months) ADT reveal higher prevalence of diabetes and metabolic syndrome compared with controls. Furthermore, men undergoing ADT also experience higher cardiovascular mortality. Conclusion: Long-term prospective studies of ADT are needed to determine the timing of onset of these metabolic complications and to investigate the mechanism behind them. In the meantime, we recommend baseline and serial screening for fasting glucose, lipids, and other cardiovascular risk factors in men receiving ADT. Glucose tolerance tests and cardiac evaluation may be required in selected cases.

Sign in / Sign up

Export Citation Format

Share Document